(AOF) – Medesis Pharma announces that it has “successfully reached a key milestone in its phase 2 clinical study for the treatment of Alzheimer’s disease”. The biotech developing drug candidates based on its proprietary technology for administering active ingredients in nanomicelles orally, Aonys, is also making public the securing of a new cash contribution of 400,000 euros. It will be finalized at the end of February and will be done on the same principles as in December 2023.
She also plans a scientific publication on treatment with NanoLithium, her participation in the Biomed Forum on January 30, 2024.
Medesis Pharma requested and obtained the opening, on September 29, 2023, of a safeguard procedure with the Montpellier Commercial Court. This can last up to twelve months and leads to the temporary suspension of its financial and tax obligations.
The resources from this next capital increase allow Medesis Pharma to extend its cash flow horizon during the month of February 2024.
AOF – LEARN MORE
Learn more about the Pharmacy sector
Oncology, priority of pharmaceutical giants
Sanofi’s stock market disappointment recorded at the end of October 2023 underlines the new direction for the group, which has now set oncology as its number 1 priority. Efforts in this segment, where therapies are advancing the fastest, notably involve investments in R&D which weigh on profitability. Sanofi therefore announced a drop in its earnings per share in 2024 and the abandonment of its objective of an operating margin of 32% in 2025. Merck has just unveiled a new alliance. It will pay up to $22 billion to the Japanese group Daiichi Sankyo as part of a partnership on experimental cancer treatments. While some experts estimate that the United States represents nearly half of global oncology spending (drugs and treatments), or $196 billion in 2022, Chinese spending in this area has more than doubled in five years, going from 5 to 11.8 billion dollars.